首页> 外国专利> DIAGNOSTIC METHOD FOR DETERMINING THE AGGRESSIVE AND PROGNOSIS OF PAPILLARY THYROID CANCER

DIAGNOSTIC METHOD FOR DETERMINING THE AGGRESSIVE AND PROGNOSIS OF PAPILLARY THYROID CANCER

机译:确定乳头状甲状腺癌的恶性和预后的诊断方法

摘要

This invention provides a diagnostic method that allows differentiating aggressive forms of PTC from non-aggressive PTC. The method involves the measurement of the CC3 expression in a thyroid FNA sample obtained from the patient that is under study. CCR3 can be measured by itself or in combination with other markers. The other makers that can be considered to determine prognosis of PTC correspond to the chemokine receptors CCR7 y CXCR4 and other any other available marker. An overexpression of CCR3 in a particular tumor correlates with its aggressive clinical parameters, such as capsule invasion and metastasis. The invention also refers to a kit to determine the prognosis of a PTC, which contains reagents for the detection of CCR3 in a thyroid tissue sample and usage instructions. In another embodiment of the invention a kit is provided to determine the prognosis of PTC, which includes reagents for the detection of PTC and other marker related to PTC. Other makers that can be quantified for the pronostic diasgnosis of PTC correspond to the chemokine CCR7, CXCR4 and/or other any other available marker.
机译:本发明提供了一种诊断方法,该诊断方法允许区分积极形式的PTC与非积极形式的PTC。该方法涉及测量从正在研究的患者获得的甲状腺FNA样品中CC3的表达。 CCR3可以单独测量,也可以与其他标记结合使用。可以考虑确定PTC预后的其他标记物对应于趋化因子受体CCR7和CXCR4以及其他任何其他可用的标记物。 CCR3在特定肿瘤中的过表达与其侵略性临床参数(如胶囊浸润和转移)相关。本发明还涉及确定PTC预后的试剂盒,其包含用于检测甲状腺组织样品中CCR3的试剂和使用说明。在本发明的另一个实施方案中,提供了一种用于确定PTC的预后的试剂盒,其包括用于检测PTC的试剂和与PTC相关的其他标记。可以定量诊断PTC的其他制造商对应于趋化因子CCR7,CXCR4和/或其他任何其他可用标记。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号